These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30209279)

  • 1. A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study.
    Chen S; Yin Q; Ren S; Zhong X; Wang W; Li G; Wang L
    Sci Rep; 2018 Sep; 8(1):13662. PubMed ID: 30209279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis.
    Yi J; He Z; Xu S; Feng S
    Int Urol Nephrol; 2019 Nov; 51(11):1987-1998. PubMed ID: 31515666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience.
    He WJ; Wang J; Liu N; Li GY; Zhu XW; Yao L; Liu LL
    J Nephrol; 2024 May; 37(4):933-940. PubMed ID: 38225440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive agents for treating IgA nephropathy.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.
    Ma F; Yang X; Zhou M; Bai M; Zhao L; Li L; Dong R; Liu C; Li R; Sun S
    J Nephrol; 2020 Dec; 33(6):1241-1250. PubMed ID: 32447619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.
    Xu K; Zhang L; Ding J; Wang S; Su B; Xiao H; Wang F; Zhong X; Li Y
    J Nephrol; 2018 Apr; 31(2):279-286. PubMed ID: 29185209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis.
    Liu T; Wang Y; Mao H; Yang L; Zhan Y
    Medicine (Baltimore); 2021 Feb; 100(8):e24541. PubMed ID: 33663060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.
    Wu H; Xia Z; Gao C; Zhang P; Yang X; Wang R; Wang M; Peng Y
    BMC Nephrol; 2020 Jul; 21(1):247. PubMed ID: 32611399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
    Vaz de Castro PAS; Bitencourt L; Pereira BWS; Lima AQR; Hermida HS; Moreira Neto CR; Mestriner MD; Simões E Silva AC
    Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
    Tan L; Tang Y; Peng W; Mathew BS; Qin W
    Kidney Blood Press Res; 2018; 43(4):1333-1343. PubMed ID: 30099439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
    Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
    Min L; Wang Q; Cao L; Zhou W; Yuan J; Zhang M; Che X; Mou S; Fang W; Gu L; Zhu M; Wang L; Yu Z; Qian J; Ni Z
    Oncotarget; 2017 Jul; 8(29):48375-48384. PubMed ID: 28415636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.
    Ni Z; Zhang Z; Yu Z; Lu F; Mei C; Ding X; Yuan W; Zhang W; Jiang G; Sun M; He L; Deng Y; Pang H; Qian J
    Ren Fail; 2021 Dec; 43(1):1214-1221. PubMed ID: 34396911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F; Ackermann D; Hilgers RD; Floege J
    J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.
    Edström Halling S; Söderberg MP; Berg UB
    Pediatr Nephrol; 2009 Jan; 24(1):91-7. PubMed ID: 18931859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy.
    Li Y; Xiong Y; Huang T; Liu X; Xu G
    BMC Nephrol; 2021 Nov; 22(1):364. PubMed ID: 34736419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T; Amamiya N; Ochi A; Tsuruta Y; Shimizu A; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
    Clin Exp Nephrol; 2011 Oct; 15(5):700-707. PubMed ID: 21625892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.